STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] ATAI Life Sciences N.V. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Atai Beckley N.V. filed a prospectus supplement covering the resale from time to time by certain selling securityholders of up to 5,316,238 common shares. The registration satisfies rights granted in connection with the Company’s acquisition of the issued share capital of Beckley Psytech Limited not already owned by the Company.

The Company also filed a legal opinion from NautaDutilh N.V. as Exhibit 5.1 regarding the validity of the shares, along with a related consent and the cover page interactive data file.

Positive
  • None.
Negative
  • None.

Insights

Administrative resale registration; no operational change disclosed.

Atai Beckley N.V. submitted a prospectus supplement enabling certain holders to resell up to 5,316,238 common shares "from time to time." This action fulfills registration rights tied to the Beckley Psytech Limited acquisition and lists the shares for potential secondary sales.

The filing includes a legal validity opinion from NautaDutilh N.V., a customary step supporting the registered securities’ status. The excerpt does not describe primary issuance, pricing, or use of proceeds; activity will depend on selling holders’ decisions.

Key elements are the resale nature, the 5,316,238 shares cap, and the acquisition link. Subsequent disclosures may detail any sales activity by the holders.



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K



CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025



Atai Beckley N.V.
(Exact name of registrant as specified in its charter)



The Netherlands
 
001-40493
 
Not Applicable
(State or other jurisdiction of
incorporation or organization)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)

Prof. J.H. Bavincklaan 7
1183 AT Amstelveen
The Netherlands
(Address of principal executive offices) (Zip Code)

+31 20 793 2536
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common shares, €0.10 par value per share
 
ATAI
 
The Nasdaq Stock Market LLC
(Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 8.01.
Other Events.

On November 5, 2025, Atai Beckley N.V. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a prospectus supplement to the prospectus included in the Company’s registration statement on Form S-3ASR (File No. 333-290592), filed with the SEC on September 29, 2025 (the “Registration Statement”), covering the resale from time to time by certain selling securityholders of up to an aggregate of 5,316,238 common shares (the “Shares”) of the Company, €0.10 par value per share, to satisfy certain registration rights the Company granted to such selling securityholders in connection with the Company’s acquisition of the entire issued share capital of Beckley Psytech Limited not already owned by the Company.

A copy of the legal opinion of NautaDutilh N.V. relating to the validity of the Shares is filed herewith as Exhibit 5.1 and is incorporated herein by reference, and is filed with reference to, and is hereby incorporated by reference into, the Registration Statement.

Item 9.01.
Financial Statements and Exhibits.

(d) Exhibits

Exhibit
 
Description
5.1
 
Opinion of NautaDutilh N.V.
     
23.1
 
Consent of NautaDutilh N.V. (included in Exhibit 5.1).
     
104
 
Cover page interactive data file (embedded within the inline XBRL document).



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
ATAI BECKLEY N.V.
     
Date: November 5, 2025
By:
/s/ Srinivas Rao
   
Srinivas Rao
   
Chief Executive Officer



Atai Beckley Inc

NASDAQ:ATAI

ATAI Rankings

ATAI Latest News

ATAI Latest SEC Filings

ATAI Stock Data

1.58B
242.21M
7.7%
39.81%
8.03%
Biotechnology
Pharmaceutical Preparations
Link
Germany
AMSTELVEEN